Literature DB >> 9880443

A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children.

R A Oberhelman1, R H Gilman, P Sheen, D N Taylor, R E Black, L Cabrera, A G Lescano, R Meza, G Madico.   

Abstract

OBJECTIVE: Lactobacillus GG (L-GG), an acid- and bile-resistant strain that colonizes the intestinal mucosa, has been used to manage diarrhea in children. Our objective was to evaluate the prophylactic use of L-GG to prevent diarrhea in children at high risk from a developing country in a randomized, placebo-controlled trial. STUDY
DESIGN: Two hundred four undernourished children 6 to 24 months old from an indigent peri-urban Peruvian town received either L-GG or placebo in flavored gelatin once daily, 6 days a week, for 15 months. Episodes of diarrhea were documented by daily home visits, and diagnostic studies were done in a subset of cases. Recovery of L-GG in stool from subjects and from family contacts was examined.
RESULTS: Subjects in the L-GG group had significantly fewer episodes of diarrhea (5.21 episodes diarrhea/child/year ['ecy'] L-GG group, 6. 02 ecy placebo group; P =.028). The decreased incidence of diarrhea in the L-GG group was greatest in the 18- to 29-month age group (P =. 004) and was largely limited to nonbreastfed children (Breastfed: 6. 59 ecy L-GG, 6.32 ecy placebo, P =.7; Nonbreastfed: 4.69 ecy L-GG, 5. 86 ecy placebo, P =.005). The duration of diarrhea episodes and the causes of diarrhea were similar in both groups, except adenovirus was more common in the placebo group.
CONCLUSION: L-GG supplementation may be useful as a prophylactic measure to control diarrhea in undernourished children at increased risk, especially nonbreastfed children in the toddler age group.

Entities:  

Keywords:  Age Factors; Americas; Demographic Factors; Developing Countries; Diarrhea; Diarrhea, Infantile; Diseases; Follow-up Studies; Infant; Latin America; Malnutrition; Nutrition Disorders; Peru; Population; Population Characteristics; Research Methodology; Research Report; South America; Studies; Treatment; Youth

Mesh:

Year:  1999        PMID: 9880443     DOI: 10.1016/s0022-3476(99)70366-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

1.  Probiotics in the Treatment of Diarrheal Diseases.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 2.  Probiotics: a role in the treatment of intestinal infection and inflammation?

Authors:  E Isolauri; P V Kirjavainen; S Salminen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  Do probiotics prevent childhood illnesses?

Authors:  C A Wanke
Journal:  BMJ       Date:  2001-06-02

Review 4.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

Review 5.  Probiotics. Some evidence of their effectiveness.

Authors:  Gregor Reid; Jo-Anne Hammond
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

Review 6.  Do probiotics have a therapeutic role in gastroenterology?

Authors:  Jimmy K Limdi; Catherine O'Neill; John McLaughlin
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

7.  Probiotics and necrotising enterocolitis in premature infants.

Authors:  R J Schanler
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

Review 8.  The impoverished gut--a triple burden of diarrhoea, stunting and chronic disease.

Authors:  Richard L Guerrant; Mark D DeBoer; Sean R Moore; Rebecca J Scharf; Aldo A M Lima
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

9.  The human microbiome and probiotics: implications for pediatrics.

Authors:  Michael H Hsieh; James Versalovic
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2008 Nov-Dec

Review 10.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.